Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Current Investments (2023 - 2025)

Historic Cash & Current Investments for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $272.6 million.

  • Immunome's Cash & Current Investments rose 1352.01% to $272.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.6 million, marking a year-over-year increase of 1352.01%. This contributed to the annual value of $217.3 million for FY2024, which is 5730.41% up from last year.
  • Immunome's Cash & Current Investments amounted to $272.6 million in Q3 2025, which was up 1352.01% from $268.1 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Cash & Current Investments peaked at $317.3 million during Q1 2025, and registered a low of $38.4 million during Q2 2023.
  • Its 3-year average for Cash & Current Investments is $201.4 million, with a median of $240.2 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 62457.57% in 2024, then plummeted by 368.35% in 2025.
  • Immunome's Cash & Current Investments (Quarter) stood at $138.1 million in 2023, then skyrocketed by 57.3% to $217.3 million in 2024, then increased by 25.46% to $272.6 million in 2025.
  • Its Cash & Current Investments was $272.6 million in Q3 2025, compared to $268.1 million in Q2 2025 and $317.3 million in Q1 2025.